Business Description
Collegium Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US19459J1043
Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.49 | |||||
| Equity-to-Asset | 0.21 | |||||
| Debt-to-Equity | 2.58 | |||||
| Debt-to-EBITDA | 1.56 | |||||
| Interest Coverage | 2.79 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 1.91 | |||||
| Beneish M-Score | -3.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.4 | |||||
| 3-Year EBITDA Growth Rate | 30 | |||||
| 3-Year EPS without NRI Growth Rate | 93.1 | |||||
| 3-Year Book Growth Rate | 4.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 7.78 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.44 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.99 | |||||
| 9-Day RSI | 55.4 | |||||
| 14-Day RSI | 55.66 | |||||
| 6-1 Month Momentum % | -7.63 | |||||
| 12-1 Month Momentum % | 69.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.11 | |||||
| Quick Ratio | 1.04 | |||||
| Cash Ratio | 0.59 | |||||
| Days Inventory | 50.44 | |||||
| Days Sales Outstanding | 112.34 | |||||
| Days Payable | 7.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2.7 | |||||
| Shareholder Yield % | 8.68 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.94 | |||||
| Operating Margin % | 35.32 | |||||
| Net Margin % | 17.32 | |||||
| FCF Margin % | 47.8 | |||||
| ROE % | 49.26 | |||||
| ROA % | 8.76 | |||||
| ROIC % | 18.11 | |||||
| 3-Year ROIIC % | 13.74 | |||||
| ROC (Joel Greenblatt) % | 962.81 | |||||
| ROCE % | 31.16 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.77 | |||||
| Forward PE Ratio | 5.67 | |||||
| PE Ratio without NRI | 6.41 | |||||
| Price-to-Owner-Earnings | 9.85 | |||||
| PS Ratio | 3 | |||||
| PB Ratio | 5.71 | |||||
| Price-to-Free-Cash-Flow | 6.29 | |||||
| Price-to-Operating-Cash-Flow | 6.26 | |||||
| EV-to-EBIT | 7.1 | |||||
| EV-to-EBITDA | 4.25 | |||||
| EV-to-Revenue | 2.64 | |||||
| EV-to-Forward-Revenue | 2.11 | |||||
| EV-to-FCF | 5.52 | |||||
| Price-to-Projected-FCF | 1.46 | |||||
| Earnings Yield (Greenblatt) % | 14.08 | |||||
| FCF Yield % | 22.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COLL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Collegium Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 576.653 | ||
| EPS (TTM) ($) | 2.59 | ||
| Beta | 0.81 | ||
| Volatility % | 36.54 | ||
| 14-Day RSI | 55.66 | ||
| 14-Day ATR ($) | 1.233531 | ||
| 20-Day SMA ($) | 37.667 | ||
| 12-1 Month Momentum % | 69.08 | ||
| 52-Week Range ($) | 20.95 - 40.95 | ||
| Shares Outstanding (Mil) | 32.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Collegium Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Collegium Pharmaceutical Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Collegium Pharmaceutical Inc Frequently Asked Questions
What is Collegium Pharmaceutical Inc(COLL)'s stock price today?
The current price of COLL is $38.26. The 52 week high of COLL is $40.95 and 52 week low is $20.95.
When is next earnings date of Collegium Pharmaceutical Inc(COLL)?
The next earnings date of Collegium Pharmaceutical Inc(COLL) is 2024-11-01 Est..
Does Collegium Pharmaceutical Inc(COLL) pay dividends? If so, how much?
Collegium Pharmaceutical Inc(COLL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers